Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Delayed Methotrexate Elimination after Administration of a Medium Dose of Methotrexate in a Patient with Genetic Variants Associated with Methotrexate Clearance.

Acta medica Okayama - 1 Dec 2020

Tatebe Yasuhisa, Kanamitsu Kiichiro, Kanzaki Hirotaka, Ishida Hisashi, Fujiwara Kaori, Washio Kana, Kitamura Yoshihisa, Sendo Toshiaki, Shimada Akira, Tsukahara Hirokazu

Abstract excerpt

Polymorphisms in methotrexate transporter pathways have been associated with methotrexate toxicities and clearance. Recent genome-wide association studies have revealed that the SLCO1B1 T521C variant is associated with methotrexate elimination. We present a case of a pediatric patient with acute lymphoblastic leukemia who suffered from persistently high plasma methotrexate concentrations and acute kidney injuries...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Child

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liver-Specific Organic Anion Transporter 1

Share to Methotrexate

Share to Methylenetetrahydrofolate Reductase (NADPH2)

Share to Polymorphism, Single Nucleotide

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Source

Identifiers

PMID: 33361876
DOI: 10.18926/AMO/61215

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Delayed Methotrexate Elimination after Administration of a Medium Dose of Methotrexate in a Patient with Genetic Variants Associated with Methotrexate Clearance.PMID 33361876Read ↗

Genetic factors involved in delayed methotrexate elimination in children with acute lymphoblastic leukemia.Semantic proximity Read ↗

Genome-wide study of methotrexate clearance replicates SLCO1B1.Semantic proximity Read ↗

Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition.Semantic proximity Read ↗

Genetic polymorphisms in low-dose methotrexate transporters: current relevance as methotrexate therapeutic outcome biomarkers.Semantic proximity Read ↗

Methotrexate Disposition in Pediatric Patients with Acute Lymphoblastic Leukemia: What Have We Learnt From the Genetic Variants of Drug TransportersSemantic proximity Read ↗

Pharmacogenetic insights into MTHFR and SLC19A1 variants in low-dose methotrexate therapy for rheumatologic diseases.Semantic proximity Read ↗

Effects of SLCO1B1 on elimination and toxicities of high-dose methotrexate in pediatric acute lymphoblastic leukemia.Semantic proximity Read ↗

Advances in individual prediction of methotrexate toxicity: a reviewSemantic proximity Read ↗

Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.Semantic proximity Read ↗

Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia.Semantic proximity Read ↗

[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].Semantic proximity Read ↗

Relationship between SLCO1B1 polymorphisms and methotrexate intolerance in Mexican children with juvenile idiopathic arthritis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.